Charles M.
Baum, M.D., Ph.D. assumes role of interim CEO
SAN
DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati
Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage
biotechnology company today announced that David Meek and the Company mutually agreed for
Mr. Meek to step down from his role as CEO and as a member of the
Board of Directors. His responsibilities have been assumed by
former CEO, president, and founder Charles
M. Baum, M.D., Ph.D., acting as interim CEO, while the
company conducts a search for a permanent CEO. Mr. Meek will remain
as a consultant to the Company through October 15, 2023.
"David has made a significant impact during his tenure at
Mirati, most notably guiding the company through the successful
launch of KRAZATI®, the rapid advancement of our robust
and innovative pipeline and the expansion of the Mirati team," said
Faheem Hasnain, chairman of the
board of directors, Mirati Therapeutics, Inc. "We are grateful for
his contributions to the company."
"I am proud of the accomplishments Mirati has achieved with the
successful launch of KRAZATI and advancing an innovative pipeline,"
said David Meek. "I had the pleasure
of working with an accomplished team, and together we have helped
to improve the lives of many people which is and will continue to
be a purpose and passion going forward."
"We extend our sincere gratitude to David for helping to advance
Mirati as a leading biotech, delivering targeted therapies to
people living with cancer," said Charles M.
Baum, M.D., Ph.D., interim CEO, founder, and president,
Mirati Therapeutics, Inc. "We look optimistically to the future and
the ability of our robust pipeline of potentially best-in-class or
first-in-class targeted oncology programs to offer the promise of a
life beyond cancer for patients and their loved ones."
About Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. is a commercial stage biotechnology
company whose mission is to discover, design and deliver
breakthrough therapies to transform the lives of patients with
cancer and their loved ones. The company is relentlessly focused on
bringing forward therapies that address areas of high unmet need,
including lung cancer, and advancing a pipeline of novel
therapeutics targeting the genetic and immunological drivers of
cancer. Unified for patients, Mirati's vision is to unlock the
science behind the promise of a life beyond cancer.
For more information about Mirati, visit us
at Mirati.com or follow us
on Twitter, LinkedIn and Facebook.
Forward Looking Statements
This press release includes forward-looking statements
regarding Mirati's business, financial guidance and the
therapeutic and commercial potential of
KRAZATI® (adagrasib), MRTX1719 (MTA-cooperative
PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133
(selective KRASG12D inhibitor), Mirati's technologies and Mirati's
other products in development. Any statement describing Mirati's
goals, expectations, intentions or beliefs, financial or other
projections, is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, including those related to the
impact COVID-19 could have on our business, and including those
inherent in the process of discovering, developing and
commercializing medicines that are safe and effective for use as
human therapeutics, and in the endeavor of building a business
around such medicines.
Mirati's forward-looking statements also involve assumptions
that, if they never materialize or prove correct, could cause its
results to differ materially from those expressed or implied by
such forward-looking statements. Although Mirati's forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Mirati. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning
Mirati's programs are described in additional detail in Mirati's
annual report on Form 10-K, and most recent Form 10-Q, which are on
file with the Securities and Exchange Commission and available at
the SEC's Internet site (https://www.sec.gov/). These
forward-looking statements are made as of the date of this press
release, and Mirati assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-departure-of-chief-executive-officer-david-meek-301896150.html
SOURCE Mirati Therapeutics, Inc.